Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 148: 112743 PMID 35228065 DOI 10.1016/j.biopha.2022.112743
Аннотация
Viral infections are a common cause of morbidity worldwide. The emergence of Coronavirus Disease 2019 (COVID-19) has led to more attention to viral infections and finding novel therapeutics. The CRISPR-Cas9 system has been recently proposed as a potential therapeutic tool for the treatment of viral diseases. Here, we review the research progress in the use of CRISPR-Cas technology for treating viral infections, as well as the strategies for improving the delivery of this gene-editing tool in vivo. Key challenges that hinder the widespread clinical application of CRISPR-Cas9 technology are also discussed, and several possible directions for future research are proposed.